

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Wei et al.

Application No.: 10/602,043

Filed: June 24, 2003

For: Human DNA Topoisomerase I Alpha



Docket No.: PF118D3C1

Confirmation No.: 9515

Art Unit: 1653

Examiner: Not Yet Assigned

REQUEST FOR CORRECTED FILING RECEIPT

Customer Service Branch
Office of Initial Patent Examination
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicant hereby requests that a corrected Filing Receipt be issued in the above-identified patent application. The official Filing Receipt received by Applicant, a copy of which is attached hereto with the correction noted thereon, has an error in:

Continuing Data as Claimed by Applicant

~~AND IS A CIP OF PCT/US94/05701 05/18/94~~ should read WHICH IS A
CIP OF PCT/US94/05701 05/18/94.

In support of the above request, Applicants attach hereto a copy of the Application Data Sheet filed with the application on June 24, 2003, as well as the PTO date-stamped copy of the postcard evidencing its receipt.

Applicant additionally requests that all pertinent U.S. Patent and Trademark Office records relating to the subject application be changed to reflect this correction.

Dated: Dec. 4, 2003

Respectfully submitted,

By 

Melissa J. Pytel

Registration No.: 41,512
HUMAN GENOME SCIENCES, INC.
9410 Key West Avenue
Rockville, Maryland 20850
(301) 610-5764

KKH/MJP/DS/KN/ba



UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/602,043	06/24/2003	1653	834	PF118D3C1	11	20	4

RECEIVED

CONFIRMATION NO. 9515

22195
 HUMAN GENOME SCIENCES INC
 9410 KEY WEST AVENUE
 ROCKVILLE, MD 20850



OCT 27 2003
 KKH MJP DS
 HGS PATENT DEPT

REPLACEMENT FILING RECEIPT



OC000000011098707

KN

Date Mailed: 10/24/2003

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Ying-Fei Wei, Berkeley, CA;
 Mark D. Adams, Rockville, MD;
 Robert D. Fleischmann, Gaithersburg, MD;

Assignment For Published Patent Application

Human Genome Sciences, Inc., Rockville, MD;

Domestic Priority data as claimed by applicant

This application is a CON of 09/871,615 06/04/2001
 which is a DIV of 09/325,430 06/04/1999 PAT 6,255,077
 which is a DIV of 09/033,153 03/02/1998 PAT 5,968,803
 which is a DIV of 08/458,477 06/02/1995 PAT 5,723,311
 and is a CIP of PCT/US94/05701 05/18/1994
 which

Foreign Applications

If Required, Foreign Filing License Granted: 09/02/2003

Projected Publication Date: To Be Determined - pending completion of Sequence Disclosures

Non-Publication Request: No

Early Publication Request: No

Title

Human DNA topoisomerase I alpha

Preliminary Class

435

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).